Graft Polymer UK PLC
LSE:GPL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (0), the stock would be worth GBX-0 (101% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2.4 | GBX0.17 |
0%
|
| Industry Average | 0 | GBX-0 |
-101%
|
| Country Average | 0 | GBX-0 |
-101%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
G
|
Graft Polymer UK PLC
LSE:GPL
|
3.8m GBP | -2.4 | -1.4 | |
| US |
|
Sherwin-Williams Co
NYSE:SHW
|
83B USD | 20.9 | 32.3 | |
| JP |
|
Shin-Etsu Chemical Co Ltd
TSE:4063
|
12.4T JPY | 12.6 | 25.6 | |
| US |
|
Ecolab Inc
NYSE:ECL
|
75.8B USD | 21.3 | 36.5 | |
| JP |
Y
|
Yasuhara Chemical Co Ltd
TSE:4957
|
10.8T JPY | 5.8 | 10.5 | |
| CN |
|
Wanhua Chemical Group Co Ltd
SSE:600309
|
273.9B CNY | 21.2 | 24.7 | |
| CH |
|
Givaudan SA
SIX:GIVN
|
26.4B CHF | 16.9 | 24.2 | |
| IN |
|
Asian Paints Ltd
NSE:ASIANPAINT
|
2.4T INR | 38.3 | 63.7 | |
| DK |
|
Novozymes A/S
CSE:NZYM B
|
165.6B DKK | 28.9 | 54.8 | |
| US |
|
PPG Industries Inc
NYSE:PPG
|
25B USD | 10.9 | 15.8 | |
| CH |
|
Sika AG
F:SIKA
|
19.9B EUR | 10.3 | 17.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 743.2 |
Other Multiples
Graft Polymer UK PLC
Glance View
Graft Polymer (UK) Ltd. is a holding company, which comprises polymer modification and drug delivery systems developments. The firm's primary business comprises polymer modification and drug delivery systems developments. The company develops range of products, including grafted polymer modifiers; nano-structured and crosslinking polymer alloys; and a variety of delivery vehicles for pharma and bio applications. Its products fall into the category of standard products, such as Polypropylene-based composites, Polyamide-based composites, and other composites; custom made products; and innovative products, such as GRAFTALLOY, GRAFTAKIT, GRAFTAMER TRC, and GRAFTAMER VTR. The firm provides three main types of modification solutions, including Graft/Block copolymers, Polymeric Nano-Structured Alloys and Crosslinking Master batches.
